Centralisation Of Ulna For Recurrence In Reconstructed Lower End Radius Giant Cell Tumor
Journal of Orthopaedics
Giant cell tumors have been extensively studied but the debate still continues on the ideal management. Treatment modalities range from simple curettage followed by packing of cavity with bone cement or grafts to more radical surgeries like enbloc resection with reconstruction. More radical procedures are associated with much higher patient morbidity. All the procedures are associated with recurrence and there is no consensus on the treatment of local recurrence.We present the case report of a 21 year male with Giant cell tumor distal radius treated initially by wide excision and reconstruction using autologous non vascularized fibula who had recurrence 2 years after the initial surgery
Available from: Athanasios N Ververidis
[Show abstract] [Hide abstract]
ABSTRACT: Giant cell tumour is a frequent benign neoplasm. It is characterized by local aggressive behaviour and frequent recurrence. The most common localization is the distal femur followed by proximal tibia (40%). The distal radius is the next place (10%). The recurrence in the distal radius in primary cases is reported 10%, in recurrent cases is almost 30% and depends to the kind and the stage of the tumour at the time of treatment. Multiple options have been reported for treatment of Campanacci III giant-cell tumour (GCT) of the distal radius after resection. Actually the treatment of recurrence remains a real dilemma. Several reconstructive options (e.g. resection arthroplasty, prosthetic replacement, arthrodesis, ulnar translocation, centralization of the carpus over the remaining ulna, use of vascularized or nonvascularized fibular graft, with or without, arthrodesis, have been described up to date.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.